Remedium Lifecare Limited Outlines Strategic Objectives of Upcoming Rights Issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited (BSE: 539561) has shared the strategic plan behind its upcoming rights issue, which was recently approved by BSE. The company has secured a multi-year export deal worth about ₹182.7 crore with a UK-based pharmaceutical partner. Money raised from the rights issue will go into a new quality control facility in Telangana, dedicated R&D labs for CNS, metabolic, and oncology therapies, prepayment of existing debt, and general corporate needs such as hiring, IT upgrades, and international marketing. Founded in 1988 and previously known as Roxy Exports, the company is positioning itself as a vertically integrated, research-driven pharma player with global reach.
Existing shareholders will get the right (and obligation) to subscribe to the rights issue, which may lead to dilution if not fully taken up. If executed well, the R&D push, debt reduction, and the UK export deal could improve revenue visibility and margins over the medium term.